Minimal Residual Disease detection by High -throughput sequencing in malignant hematological patients after chimeric antigen receptor T cells treatment

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018468

Enrollment

Unknown

Registered

2018-09-20

Start date

2018-09-17

Completion date

Unknown

Last updated

2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy

Interventions

Case series:IGH etc sequencing after CAR-T cell treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received CAR-T treatment and achieved complete remission

Exclusion criteria

Exclusion criteria: No bone marrow samples kept for research

Design outcomes

Primary

Measure	Time frame
Minimal Residual Disease;Overall survival rate;remission rate;	—

Countries

China

Contacts

Public ContactHe Huang

the First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026